Mark S. Shearman

Mark S. Shearman is an accomplished biotechnology executive with extensive experience in drug development across multiple therapeutic areas, including neurology, ophthalmology, and gene therapy. Currently serving as Chief Executive Officer and Advisory Board Chair at APRINOIA Therapeutics since 2021, Mark Shearman also founded Sharp Focus Consulting LLC in 2022. Previous roles include Chief Scientific Officer and Executive Vice-President at Editas Medicine, Chief Scientific Officer at AGTC, and Senior Vice-President at EMD Serono, where strategic portfolios were developed for neurological disorders. Mark Shearman's career began at Merck, where responsibilities included leading drug discovery in neuroscience and overseeing Alzheimer's disease therapeutic area. Mark holds a Ph.D. in Biochemistry from the University of Nottingham and post-doctoral fellowships from the Max Planck Institute and Kobe University School of Medicine.